LKFT NASDAQ
Lakefront Biotherapeutics N.V.
1W: +6.4%
1M: +7.9%
3M: +12.6%
YTD: -3.9%
1Y: -1.1%
3Y: -8.0%
5Y: -38.6%
$31.82
+0.14 (+0.43%)
After Hours: $30.50 (-1.32, -4.15%)
Weekly Expected Move ±3.5%
$29
$31
$32
$33
$34
Credit Risk of going bust: not rated Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range25.68-36.24
Volume191,347
Avg Volume246,289
Beta0.12
Dividend—
Analyst Ratings
Company Info
CEOHenry Gosebruch
Employees452
SectorHealthcare
IndustryBiotechnology
IPO Date2005-05-05
Websitelakefrontbio.com
SchaliEnhoevedreef 20 T
Mechelen 2800
BE
Mechelen 2800
BE
32 1 534 29 00
About Lakefront Biotherapeutics N.V.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Recent Insider Trades
No insider trades found